UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10‑Q
(Mark One) |
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended March 31, 2018 |
|
Or |
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to |
Commission File No. 1‑6639
MAGELLAN HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware |
58‑1076937 |
4800 N. Scottsdale Rd, Suite 4400 |
85251 |
(602) 572‑6050
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S‑T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b‑2 of the Exchange Act. (Check one):
Large accelerated filer ☒ |
Accelerated filer ☐ |
Non‑accelerated filer ☐ |
|
Smaller reporting company ☐ |
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No ☒
The number of shares of the registrant’s Ordinary Common Stock outstanding as of March 31, 2018 was 24,627,170.
FORM 10‑Q
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
1
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
(In thousands, except per share amounts)
|
|
|
|
|
March 31, |
|
|
|
|
December 31, |
|
2018 |
|
||
|
|
2017 |
|
(Unaudited) |
|
||
ASSETS |
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
Cash and cash equivalents ($229,013 and $170,575 restricted at December 31, 2017 and March 31, 2018, respectively) |
|
$ |
398,732 |
|
$ |
394,326 |
|
Accounts receivable, net |
|
|
660,775 |
|
|
748,060 |
|
Short-term investments ($219,111 and $265,112 restricted at December 31, 2017 and March 31, 2018, respectively) |
|
|
310,578 |
|
|
329,710 |
|
Pharmaceutical inventory |
|
|
40,945 |
|
|
37,878 |
|
Other current assets ($41,121 and $49,939 restricted at December 31, 2017 and March 31, 2018, respectively) |
|
|
72,323 |
|
|
108,872 |
|
Total Current Assets |
|
|
1,483,353 |
|
|
1,618,846 |
|
Property and equipment, net |
|
|
158,638 |
|
|
159,857 |
|
Long-term investments ($17,287 and $20,811 restricted at December 31, 2017 and March 31, 2018, respectively) |
|
|
17,287 |
|
|
20,811 |
|
Deferred income taxes |
|
|
813 |
|
|
1,128 |
|
Other long-term assets |
|
|
22,567 |
|
|
21,489 |
|
Goodwill |
|
|
1,006,288 |
|
|
1,013,313 |
|
Other intangible assets, net |
|
|
268,288 |
|
|
256,293 |
|
Total Assets |
|
$ |
2,957,234 |
|
$ |
3,091,737 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
Accounts payable |
|
$ |
74,300 |
|
$ |
73,084 |
|
Accrued liabilities |
|
|
193,635 |
|
|
246,909 |
|
Short-term contingent consideration |
|
|
6,892 |
|
|
6,892 |
|
Medical claims payable |
|
|
327,625 |
|
|
390,098 |
|
Other medical liabilities |
|
|
177,002 |
|
|
207,220 |
|
Current debt and capital lease obligations |
|
|
112,849 |
|
|
61,498 |
|
Total Current Liabilities |
|
|
892,303 |
|
|
985,701 |
|
Long-term debt and capital lease obligations |
|
|
740,888 |
|
|
736,688 |
|
Deferred income taxes |
|
|
12,298 |
|
|
11,170 |
|
Tax contingencies |
|
|
14,226 |
|
|
14,743 |
|
Long-term contingent consideration |
|
|
1,925 |
|
|
2,158 |
|
Deferred credits and other long-term liabilities |
|
|
19,100 |
|
|
36,148 |
|
Total Liabilities |
|
|
1,680,740 |
|
|
1,786,608 |
|
Preferred stock, par value $.01 per share |
|
|
|
|
|
|
|
Authorized—10,000 shares at December 31, 2017 and March 31, 2018-Issued and outstanding-none |
|
|
— |
|
|
— |
|
Ordinary common stock, par value $.01 per share |
|
|
|
|
|
|
|
Authorized—100,000 shares at December 31, 2017 and December 31, 2018-Issued and outstanding-52,973 and 24,202 shares at December 31, 2017, respectively, and 53,398 and 24,627 shares at March 31, 2018, respectively |
|
|
530 |
|
|
534 |
|
Other Stockholders’ Equity: |
|
|
|
|
|
|
|
Additional paid-in capital |
|
|
1,274,811 |
|
|
1,296,536 |
|
Retained earnings |
|
|
1,399,495 |
|
|
1,406,720 |
|
Accumulated other comprehensive loss |
|
|
(380) |
|
|
(699) |
|
Treasury stock, at cost, 28,771 and 28,771 shares at December 31, 2017 and March 31, 2018, respectively |
|
|
(1,397,962) |
|
|
(1,397,962) |
|
Total Stockholders’ Equity |
|
|
1,276,494 |
|
|
1,305,129 |
|
Total Liabilities and Stockholders’ Equity |
|
$ |
2,957,234 |
|
$ |
3,091,737 |
|
See accompanying notes to consolidated financial statements.
2
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)
|
|
Three Months Ended |
|
|
||||
|
|
March 31, |
|
|
||||
|
|
2017 |
|
2018 |
|
|
||
Net revenue: |
|
|
|
|
|
|
|
|
Managed care and other |
|
$ |
729,340 |
|
$ |
1,219,763 |
|
|
PBM |
|
|
576,283 |
|
|
585,314 |
|
|
Total net revenue |
|
|
1,305,623 |
|
|
1,805,077 |
|
|
Costs and expenses: |
|
|
|
|
|
|
|
|
Cost of care |
|
|
482,054 |
|
|
928,661 |
|
|
Cost of goods sold |
|
|
542,633 |
|
|
559,665 |
|
|
Direct service costs and other operating expenses (1)(2) |
|
|
221,486 |
|
|
269,077 |
|
|
Depreciation and amortization |
|
|
26,976 |
|
|
30,407 |
|
|
Interest expense |
|
|
4,148 |
|
|
8,366 |
|
|
Interest and other income |
|
|
(949) |
|
|
(2,476) |
|
|
Total costs and expenses |
|
|
1,276,348 |
|
|
1,793,700 |
|
|
Income before income taxes |
|
|
29,275 |
|
|
11,377 |
|
|
Provision (benefit) for income taxes |
|
|
11,806 |
|
|
(75) |
|
|
Net income |
|
|
17,469 |
|
|
11,452 |
|
|
Less: net loss attributable to non-controlling interest |
|
|
(278) |
|
|
— |
|
|
Net income attributable to Magellan |
|
$ |
17,747 |
|
$ |
11,452 |
|
|
Net income attributable to Magellan per common share: |
|
|
|
|
|
|
|
|
Basic (See Note B) |
|
$ |
0.77 |
|
$ |
0.47 |
|
|
Diluted (See Note B) |
|
$ |
0.74 |
|
$ |
0.45 |
|
|
(1) |
Includes stock compensation expense of $10,140 and $7,646 for the three months ended March 31, 2017 and 2018, respectively. |
(2) |
Includes changes in fair value of contingent consideration of $(49) and $233 for the three months ended March 31, 2017 and 2018, respectively. |
See accompanying notes to consolidated financial statements.
3
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In thousands)
|
|
Three Months Ended |
|
||||
|
|
March 31, |
|
||||
|
|
2017 |
|
2018 |
|
||
Net income |
|
$ |
17,469 |
|
$ |
11,452 |
|
Other comprehensive income: |
|
|
|
|
|
|
|
Unrealized loss on available-for-sale securities (1) |
|
|
(21) |
|
|
(319) |
|
Comprehensive income |
|
|
17,448 |
|
|
11,133 |
|
Less: comprehensive loss attributable to non-controlling interest |
|
|
(278) |
|
|
— |
|
Comprehensive income attributable to Magellan |
|
$ |
17,726 |
|
$ |
11,133 |
|
(1) |
Net of income tax benefit of $12 and $101 for the three months ended March 31, 2017 and 2018, respectively. |
See accompanying notes to consolidated financial statements.
4
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31,
(Unaudited)
(In thousands)
|
|
2017 |
|
2018 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
|
Net income |
|
$ |
17,469 |
|
$ |
11,452 |
|
Adjustments to reconcile net income to net cash from operating activities: |
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
26,976 |
|
|
30,407 |
|
Non-cash interest expense |
|
|
253 |
|
|
307 |
|
Non-cash stock compensation expense |
|
|
10,140 |
|
|
7,646 |
|
Non-cash income tax (benefit) provision |
|
|
(1,010) |
|
|
62 |
|
Non-cash amortization on investments |
|
|
1,112 |
|
|
809 |
|
Changes in assets and liabilities, net of effects from acquisitions of businesses: |
|
|
|
|
|
|
|
Accounts receivable, net |
|
|
(27,699) |
|
|
(87,178) |
|
Pharmaceutical inventory |
|
|
(3,379) |
|
|
3,067 |
|
Other assets |
|
|
(1,172) |
|
|
(37,914) |
|
Accounts payable and accrued liabilities |
|
|
(52,838) |
|
|
26,529 |
|
Medical claims payable and other medical liabilities |
|
|
(5,160) |
|
|
107,569 |
|
Contingent consideration |
|
|
(49) |
|
|
233 |
|
Tax contingencies |
|
|
506 |
|
|
448 |
|
Deferred credits and other long-term liabilities |
|
|
4,150 |
|
|
17,685 |
|
Other |
|
|
(421) |
|
|
(90) |
|
Net cash (used in) provided by operating activities |
|
|
(31,122) |
|
|
81,032 |
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
Capital expenditures |
|
|
(10,939) |
|
|
(19,502) |
|
Acquisitions and investments in businesses, net of cash acquired |
|
|
(200) |
|
|
— |
|
Purchase of investments |
|
|
(141,432) |
|
|
(142,886) |
|
Maturity of investments |
|
|
131,840 |
|
|
118,999 |
|
Net cash used in investing activities |
|
|
(20,731) |
|
|
(43,389) |
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
Proceeds from issuance of debt |
|
|
200,000 |
|
|
— |
|
Proceeds from exercise of stock options |
|
|
4,945 |
|
|
16,897 |
|
Payments on debt and capital lease obligations |
|
|
(182,738) |
|
|
(55,895) |
|
Other |
|
|
(1,275) |
|
|
(3,051) |
|
Net cash provided by (used in) financing activities |
|
|
20,932 |
|
|
(42,049) |
|
Net decrease in cash and cash equivalents |
|
|
(30,921) |
|
|
(4,406) |
|
Cash and cash equivalents at beginning of period |
|
|
304,508 |
|
|
398,732 |
|
Cash and cash equivalents at end of period |
|
$ |
273,587 |
|
$ |
394,326 |
|
|
|
|
|
|
|
|
|
Supplemental cash flow data: |
|
|
|
|
|
|
|
Non-cash investing activities: |
|
|
|
|
|
|
|
Property and equipment acquired under capital leases |
|
$ |
906 |
|
$ |
51 |
|
See accompanying notes to consolidated financial statements.
5
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2018
(Unaudited)
Basis of Presentation
The accompanying unaudited consolidated financial statements of Magellan Health, Inc., a Delaware corporation (“Magellan”), include Magellan and its subsidiaries (together with Magellan, the “Company”). The financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the Securities and Exchange Commission’s (the “SEC”) instructions to Form 10-Q. Accordingly, the financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation, have been included. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.
These unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2017 and the notes thereto, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2018.
Business Overview
The Company is a leader within the healthcare management business, and is focused on delivering innovative specialty solutions for the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits, and other specialty carve-out areas of healthcare. The Company develops innovative solutions that combine advanced analytics, agile technology and clinical excellence to drive better decision making, positively impact members’ health outcomes and optimize the cost of care for the customers we serve. The Company provides services to health plans and other managed care organizations (“MCOs”), employers, labor unions, various military and governmental agencies and third party administrators (“TPAs”). Magellan operates three segments: Healthcare, Pharmacy Management and Corporate.
Healthcare
The Healthcare segment (“Healthcare”) consists of two reporting units – Commercial and Government.
The Commercial reporting unit’s customers include health plans, accountable care organizations (“ACOs”), and employers for whom Magellan provides carve-out management services for behavioral health, employee assistance plans (“EAP”), and other areas of specialty healthcare including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine. These management services are applied to a health plan’s or ACO’s entire book of business including commercial, Medicaid and Medicare members or targeted complex populations.
The Government reporting unit contracts with local, state and federal governmental agencies to provide services to recipients under Medicaid, Medicare and other government programs. Currently these management services include behavioral health and EAP. The management of total medical cost, as well as long term support services, for special populations is delivered through Magellan Complete Care (“MCC”). These special populations include individuals with serious mental illness (“SMI”), dual eligibles, aged, blind and disabled (“ABD”) and other populations with unique and often complex healthcare needs.
Magellan’s coordination and management of these healthcare and long term support services are provided through its comprehensive network of medical and behavioral health professionals, clinics, hospitals, skilled nursing facilities, home care agencies and ancillary service providers. This network of credentialed providers is integrated with clinical and quality improvement programs to improve access to care and enhance the healthcare experience for individuals in need of care, while at the same time making the cost of these services more affordable for our customers. The Company generally does not directly provide or own any provider of treatment services, although it does employ licensed behavioral health counselors to deliver non‑medical counseling under certain government contracts.
6
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
The Company provides its Healthcare management services primarily through: (i) risk‑based products, where the Company assumes all or a substantial portion of the responsibility for the cost of providing treatment services in exchange for a fixed per member per month fee, or (ii) administrative services only (“ASO”) products, where the Company provides services such as utilization review, claims administration and/or provider network management, but does not assume full responsibility for the cost of the treatment services, in exchange for an administrative fee and, in some instances, a gain share.
Pharmacy Management
The Pharmacy Management segment (“Pharmacy Management”) is comprised of products and solutions that provide clinical and financial management of pharmaceuticals paid under both the medical and the pharmacy benefit. Pharmacy Management’s services include: (i) pharmacy benefit management (“PBM”) services, including pharmaceutical dispensing operations; (ii) pharmacy benefit administration (“PBA”) for state Medicaid and other government sponsored programs; (iii) clinical and formulary management programs; (iv) medical pharmacy management programs; and (v) programs for the integrated management of specialty drugs across both the medical and pharmacy benefit that treat complex conditions, regardless of site of service, method of delivery, or benefit reimbursement.
These services are available individually, in combination, or in a fully integrated manner. The Company markets its pharmacy management services to health plans, employers, third party administrators, managed care organizations, state governments, Medicare Part D, and other government agencies, exchanges, brokers and consultants. In addition, the Company will continue to upsell its pharmacy products to its existing customers and market its pharmacy solutions to the Healthcare customer base.
Pharmacy Management contracts with its customers for services using risk‑based, gain share or ASO arrangements. In addition, Pharmacy Management provides services to the Healthcare segment for its MCC business.
Corporate
This segment of the Company is comprised primarily of amounts not allocated to the Healthcare and Pharmacy Management segments that are largely associated with costs related to being a publicly traded company.
Summary of Significant Accounting Policies
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”), which is a new comprehensive revenue recognition standard that will supersede virtually all existing revenue guidance under GAAP. The FASB also issued various ASUs which subsequently amended ASU 2014-09. These amendments and ASU 2014-09, collectively known as Accounting Standard Codification 606 (“ASC 606”), are effective for annual and interim reporting periods of public entities beginning after December 15, 2017. The Company adopted ASC 606 on a modified retrospective basis on January 1, 2018. The Company applied the standard to contracts not completed at the date of initial application. The Company recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. For contracts that were modified before January 1, 2018 the Company has not retrospectively restated the contracts for those modifications in accordance with the contract modification guidance, instead the Company reflected the aggregate effect of those modifications when identifying the satisfied and unsatisfied performance obligations, determining the transaction price and allocating the transaction price to the satisfied and unsatisfied performance obligation. Given the nature of our arrangements, the Company does not believe the use of this practical expedient had a significant impact on the results of our adoption.
A majority of our managed care revenue continues to be recognized over the applicable coverage period on a per member basis for covered members. In addition a majority of the PBM revenue continues to be recognized as the
7
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
claims are adjudicated or when the drugs are dispensed. The main impacts of ASC 606 to the Company’s business relate to the timing of revenue recognition in relation to upfront fees in certain PBA contracts, as well as performance incentive, performance guarantee and risk share arrangements. Some of the Company’s PBA contracts contain upfront fees, which under ASC 605 were amortized over the life of the contract. Under ASC 606, these upfront fees constitute a material right and are amortized over the anticipated life of the customer. Certain contracts include performance incentive, performance guarantee and risk share arrangements, which under ASC 605 were recorded based on calculations using the current period’s data. Under ASC 606, the revenues are recognized on a probability weighted approach based on anticipated outcomes for the performance period. In addition, under ASC 606 the accounting for material rights in relation to some of the Company’s government contracts will impact the consolidated balance sheets for interim reporting periods.
The cumulative effect of changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASU 2014-09 were as follows (in thousands):
|
Balance at December 31, 2017 |
|
Adjustments Due to ASC 606 |
|
Balance at January 1, 2018 |
|||
Assets |
|
|
|
|
|
|
|
|
Other current assets |
$ |
72,323 |
|
$ |
(667) |
|
$ |
71,656 |
Total Current Assets |
|
1,483,353 |
|
|
(667) |
|
|
1,482,686 |
Deferred income taxes |
|
813 |
|
|
1,335 |
|
|
2,148 |
Other long-term assets |
|
22,567 |
|
|
(1,333) |
|
|
21,234 |
Total Assets |
|
2,957,234 |
|
|
(665) |
|
|
2,956,569 |
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
Accrued liabilities |
|
193,635 |
|
|
(2,182) |
|
|
191,453 |
Total Current Liabilities |
|
892,303 |
|
|
(2,182) |
|
|
890,121 |
Deferred credits and other long-term liabilities |
|
19,100 |
|
|
5,744 |
|
|
24,844 |
Total Liabilities |
|
1,680,740 |
|
|
3,562 |
|
|
1,684,302 |
Retained earnings |
|
1,399,495 |
|
|
(4,227) |
|
|
1,395,268 |
Total Stockholders' Equity |
|
1,276,494 |
|
|
(4,227) |
|
|
1,272,267 |
Total Liabilities and Stockholders' Equity |
|
2,957,234 |
|
|
(665) |
|
|
2,956,569 |
The impact of the adoption of ASC 606 on our consolidated balance sheet as of March 31, 2018 was as follows (in thousands):
|
As Reported |
|
Adjustments |
|
Balance Without ASC 606 Adoption |
|
|||
Assets |
|
|
|
|
|
|
|
|
|
Accounts receivable |
$ |
748,060 |
|
$ |
(28,336) |
|
$ |
719,724 |
|
Other current assets |
|
108,872 |
|
|
(297) |
|
|
108,575 |
|
Total Current Assets |
|
1,618,846 |
|
|
(28,633) |
|
|
1,590,213 |
|
Other long-term assets |
|
21,489 |
|
|
9,483 |
|
|
30,972 |
|
Total Assets |
|
3,091,737 |
|
|
(19,150) |
|
|
3,072,587 |
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
|
Accrued liabilities |
|
246,909 |
|
|
(21,154) |
|
|
225,755 |
|
Total Current Liabilities |
|
985,701 |
|
|
(21,154) |
|
|
964,547 |
|
Deferred credits and other long-term liabilities |
|
36,148 |
|
|
(6,289) |
|
|
29,859 |
|
Total Liabilities |
|
1,786,608 |
|
|
(27,443) |
|
|
1,759,165 |
|
Retained earnings |
|
1,406,720 |
|
|
8,293 |
|
|
1,415,013 |
|
Total Stockholders' Equity |
|
1,305,129 |
|
|
8,293 |
|
|
1,313,422 |
|
Total Liabilities and Stockholders' Equity |
|
3,091,737 |
|
|
(19,150) |
|
|
3,072,587 |
|
8
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
The impact of the adoption of ASC 606 on our consolidated income statement for the three months ended March 31, 2018 was as follows (in thousands):
|
As Reported |
|
Adjustments |
|
Balance Without ASC 606 Adoption |
|||
Managed care and other |
$ |
1,219,763 |
|
$ |
(2,755) |
|
$ |
1,217,008 |
PBM |
|
585,314 |
|
|
6,450 |
|
|
591,764 |
Total net revenue |
|
1,805,077 |
|
|
3,695 |
|
|
1,808,772 |
Income before income taxes |
|
11,377 |
|
|
3,695 |
|
|
15,072 |
(Benefit) provision for income taxes |
|
(75) |
|
|
964 |
|
|
889 |
Net income |
|
11,452 |
|
|
2,731 |
|
|
14,183 |
Net income attributable to Magellan |
|
11,452 |
|
|
2,731 |
|
|
14,183 |
In February 2016, the FASB issued ASU No. 2016‑02, “Leases” (“ASU 2016‑02”). This ASU amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2018, with early adoption permitted. The Company is currently assessing the impact of adoption, but believes the effect of this ASU will have a material effect on the Company’s consolidated balance sheets. The Company is currently assessing the potential impact this ASU will have on the Company’s consolidated results of operations, financial position and cash flows.
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). This ASU amends the accounting on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. This guidance is effective for annual and interim periods of public entities beginning after December 15, 2019, with early adoption permitted for fiscal years beginning after December 31, 2018. The Company is currently assessing the potential impact this ASU will have on the Company’s consolidated results of operation, financial position and cash flows.
In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). This ASU makes eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. This guidance is effective for annual and interim periods of public entities beginning after December 15, 2017 and was adopted by the Company in the quarter ended March 31, 2018. The effect of this guidance was immaterial to the Company’s consolidated results of operations, financial position and cash flows.
In October 2016, the FASB issued ASU 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory” (“ASU 2016-16”). The amendments in this ASU require that entities recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for annual and interim periods of public entities beginning after December 15, 2017 and was adopted by the Company in the quarter ended March 31, 2018. The effect of this guidance was immaterial to the Company’s consolidated results of operations, financial position and cash flows.
In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). The amendments in this ASU clarify whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This guidance is effective for annual and interim periods of public entities beginning after December 15, 2017 and was adopted by the Company in the quarter ended March 31, 2018. The effect of this guidance was immaterial to the Company’s consolidated results of operations, financial position and cash flows.
In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). The amendments in this ASU eliminate the
9
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. This guidance is effective for annual and interim periods of public entities beginning after December 15, 2019, with early adoption permitted. The Company is currently assessing the potential impact this ASU will have on the Company’s consolidated results of operations, financial position and cash flows.
In May 2017, the FASB issued ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”). The amendments in this ASU include guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. This guidance is effective for annual and interim periods of public entities beginning after December 15, 2017 and was adopted by the Company in the quarter ended March 31, 2018. The effect of this guidance was immaterial to the Company’s consolidated results of operations, financial position and cash flows.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, valuation allowances for deferred tax assets, valuation of goodwill and intangible assets, medical claims payable, other medical liabilities, contingent consideration, stock compensation assumptions, tax contingencies and legal liabilities. In addition, the Company makes significant estimates in relation to revenue recognition under ASC 606 which are explained in more detail in “Revenue Recognition” below. Actual results could differ from those estimates.
10
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
Revenue Recognition
Virtually all of the Company’s revenues are derived from business in North America. The following table disaggregates our revenue by major service line, type of customer and timing of revenue recognition (in thousands):
|
Three months ended March 31, 2018 |
||||||||||
|
Healthcare |
|
Pharmacy Management |
|
Elimination |
|
Total |
||||
Major Service Lines |
|
|
|
|
|
|
|
|
|
|
|
Commercial |
|
|
|
|
|
|
|
|
|
|
|
Risk-based, non-EAP |
$ |
234,391 |
|
$ |
— |
|
$ |
— |
|
$ |
234,391 |
EAP risk-based |
|
12,421 |
|
|
— |
|
|
— |
|
|
12,421 |
ASO |
|
52,569 |
|
|
7,300 |
|
|
(145) |
|
|
59,724 |
Government |
|
|
|
|
|
|
|
|
|
|
|
Risk-based, non-EAP |
|
752,490 |
|
|
— |
|
|
— |
|
|
752,490 |
EAP risk-based |
|
82,237 |
|
|
— |
|
|
— |
|
|
82,237 |
ASO |
|
23,493 |
|
|
— |
|
|
— |
|
|
23,493 |
PBM, including dispensing |
|
— |
|
|
533,792 |
|
|
(46,884) |
|
|
486,908 |
Medicare Part D |
|
— |
|
|
98,406 |
|
|
— |
|
|
98,406 |
PBA |
|
— |
|
|
33,546 |
|
|
— |
|
|
33,546 |
Formulary management |
|
— |
|
|
20,377 |
|
|
— |
|
|
20,377 |
Other |
|
— |
|
|
1,084 |
|
|
— |
|
|
1,084 |
Total net revenue |
$ |
1,157,601 |
|
$ |
694,505 |
|
$ |
(47,029) |
|
$ |
1,805,077 |
|
|
|
|
|
|
|
|
|
|
|
|
Type of Customer |
|
|
|
|
|
|
|
|
|
|
|
Government |
$ |
858,220 |
|
$ |
228,049 |
|
$ |
— |
|
$ |
1,086,269 |
Non-government |
|
299,381 |
|
|
466,456 |
|
|
(47,029) |
|
|
718,808 |
Total net revenue |
$ |
1,157,601 |
|
$ |
694,505 |
|
$ |
(47,029) |
|
$ |
1,805,077 |
|
|
|
|
|
|
|
|
|
|
|
|
Timing of Revenue Recognition |
|
|
|
|
|
|
|
|
|
|
|
Transferred at a point in time |
$ |
— |
|
$ |
632,198 |
|
$ |
(46,884) |
|
$ |
585,314 |
Transferred over time |
|
1,157,601 |
|
|
62,307 |
|
|
(145) |
|
|
1,219,763 |
Total net revenue |
$ |
1,157,601 |
|
$ |
694,505 |
|
$ |
(47,029) |
|
$ |
1,805,077 |
Per Member Per Month (“PMPM”) Revenue. Almost all of the Healthcare revenue and a small portion of the Pharmacy Management revenue is paid on a PMPM basis. PMPM revenue is inclusive of revenue from the Company’s risk, EAP and ASO contracts and primarily relates to managed care contracts for services such as the provision of behavioral healthcare, specialty healthcare, pharmacy management, or fully integrated healthcare services. PMPM contracts generally have a term of one year or longer, with the exception of government contracts where the customer can terminate with as little as 30 days’ notice for no significant penalty. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is entirely variable as it primarily includes per member per month fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for things such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using an expected value methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company’s net PMPM transaction price relates specifically to its efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue in the month in which members are entitled to service. The remaining transaction price is recognized over the contract period (or portion of the series to which it specifically relates) based upon estimated membership as a measure of progress.
11
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
Pharmacy Benefit Management Revenue. The Company’s customers for PBM business, including pharmaceutical dispensing operations, are generally comprised of MCOs, employer groups and health plans. PBM relationships generally have an expected term of one year or longer. A master services arrangement (“MSA”) is executed by the Company and the customer, which outlines the terms and conditions of the PBM services to be provided. When a member in the customer’s organization submits a prescription, a claim is created which is presented for approval. The acceptance of each individual claim creates enforceable rights and obligations for each party and represents a separate contract. For each individual claim, the performance obligations are limited to the processing and adjudication of the claim, or dispensing of the products purchased. Generally, the transaction price for PBM services is explicitly listed in each contract and does not represent variable consideration. The Company recognizes PBM revenue, which consists of a negotiated prescription price (ingredient cost plus dispensing fee), co‑payments and any associated administrative fees, when claims are adjudicated or the drugs are shipped. The Company recognizes PBM revenue on a gross basis (i.e. including drug costs and co‑payments) as it is acting as the principal in the arrangement, controls the underlying service, and is contractually obligated to its clients and network pharmacies, which is a primary indicator of gross reporting. In addition, the Company is solely responsible for the claims adjudication process, negotiating the prescription price for the pharmacy, collection of payments from the client for drugs dispensed by the pharmacy, and managing the total prescription drug relationship with the client’s members. If the Company enters into a contract where it is only an administrator, and does not assume any of the risks previously noted, revenue will be recognized on a net basis. For dispensing, at the time of shipment, the earnings process is complete; the obligation of the Company’s customer to pay for the specialty pharmaceutical drugs is fixed, and, due to the nature of the product, the member may neither return the specialty pharmaceutical drugs nor receive a refund.
Medicare Part D. The Company is contracted with the Centers for Medicare and Medicaid (“CMS”) as a Prescription Drug Plan (“PDP”) to provide prescription drug benefits to Medicare beneficiaries. The accounting for Medicare Part D revenue is primarily the same as that for PBM, as previously discussed. However, there is certain variable consideration present only in Medicare Part D arrangements. The Company estimates the annual amount of variable consideration using a most likely amount methodology, which is allocated to each reporting period based upon actual utilization as a percentage of estimated utilization for the year. Amounts estimated throughout the year for interim reporting are substantially resolved and fixed as of December 31st, the end of the plan year.
Pharmacy Benefit Administration Revenue. The Company provides Medicaid pharmacy services to states and other government sponsored programs. PBA contracts are generally multi-year arrangements but include language regarding early termination for convenience without material penalty provisions that results in enforceable rights and obligations on a month-to-month basis. In PBA arrangements, the Company is generally paid a fixed fee per month to provide PBA services. In addition, some PBA contracts contain upfront fees that constitute a material right. For contracts without an upfront fee, there is a single performance obligation to stand ready to provide the PBA services required for the contracted period. The Company believes that the customer receives the PBA benefits each day from access to the claims processing activities, and has concluded that a time based measure is appropriate for recognizing PBA revenue. For contracts with an upfront fee, the material right represents an additional performance obligation. Amounts allocated to the material right are initially recorded as a contract liability and recognized as revenue over the anticipated period of benefit of the material right, which generally ranges from 2 to 10 years.
Formulary Management Revenue. The Company administers formulary management programs for certain clients through which the Company coordinates the achievement, calculation and collection of rebates and administrative fees from pharmaceutical manufacturers on behalf of clients. Formulary management contracts generally have a term of one year or longer. All formulary management contracts have a single performance obligation that constitutes a series for the provision of rebate services for a drug, with utilization measured and settled on a quarterly basis, for the duration of the arrangement. The Company retains its administrative fee and/or a percentage of rebates that is included in its contract with the client from collecting the rebate from the manufacturer. While the administrative fee and/or the percentage of rebates retained is fixed, there is an unknown quantity of pharmaceutical purchases (utilization) during each quarter, therefore the transaction price itself is variable. The Company uses the expected value methodology to estimate the total rebates earned each quarter based on estimated volumes of pharmaceutical purchases by the Company’s clients during the quarter, as well as historical and/or anticipated retained rebate percentages. The Company does not record as rebate revenue any rebates that are passed through to its clients.
12
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
In relation to the Company’s PBM business, the Company administers rebate programs through which it receives rebates from pharmaceutical manufacturers that are shared with its customers. The Company recognizes rebates when the Company is entitled to them and when the amounts of the rebates are determinable. The amount recorded for rebates earned by the Company from the pharmaceutical manufacturers is recorded as a reduction of cost of goods sold.
Government EAP Risk Based Revenue. The Company has certain contracts with federal customers for the provision of various managed care services, which are classified as government EAP risk based business. These contracts are generally multi-year arrangements. The Company’s federal contracts are reimbursed on either a fixed fee basis or a cost reimbursement basis. The performance obligation on a fixed fee contract is to stand ready to provide the staffing required for the contracted period. For fixed fee contracts, the Company believes the invoiced amount corresponds directly with the value to the customer of the Company’s performance completed to date, therefore the Company is utilizing the “right to invoice” practical expedient, with revenue recognition in the amount for which the Company has the right to invoice.
The performance obligation on a cost reimbursement contract is to stand ready to provide the activity or services purchased by the customer, such as the operation of a counseling services group or call center. The performance obligation represents a series for the duration of the arrangement. The reimbursement rate is fixed per the contract, however the level of activity (e.g., number of hours, number of counselors or number of units) is variable. A majority of the Company’s cost reimbursement transaction price relates specifically to its efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue when the portion of the series for which it relates has been provided (i.e. as the Company provides hours, counselors or units of service).
In accordance with ASC 606-10-50-13, the Company is required to include disclosure on its remaining performance obligations as of the end of the current reporting period. Due to the nature of the contracts in the Company’s PBM and Part D business, these reporting requirements are not applicable. The majority of the Company’s remaining contracts meet certain exemptions as defined in ASC 606-10-50-14 through 606-10-50-14A, including (i) performance obligation is part of a contract that has an original expected duration of one year or less; (ii) the right to invoice practical expedient; and (iii) variable consideration related to unsatisfied performance obligations that is allocated entirely to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation, and the terms of that variable consideration relate specifically to our efforts to transfer the distinct service, or to a specific outcome from transferring the distinct service. For the Company’s contracts that pertain to these exemptions: (i) the remaining performance obligations primarily relate to the provision of managed healthcare services to the customers’ membership; (ii) the estimated remaining duration of these performance obligations ranges from the remainder of the current calendar year to three years; and (iii) variable consideration for these contracts primarily includes net per member per month fees associated with unspecified membership that fluctuates throughout the contract.
Accounts Receivable, Contract Assets and Contract Liabilities
Accounts receivable, contract assets and contract liabilities consisted of the following (in thousands, except percentages):
|
January 1, 2018 |
|
March 31, 2018 |
|
$ Change |
|
% Change |
|
||||
Accounts receivable |
$ |
679,269 |
|
$ |
778,556 |
|
$ |
99,287 |
|
|
14.6% |
|
Contract assets |
|
8,564 |
|
|
5,519 |
|
|
(3,045) |
|
|
(35.6%) |
|
Contract liabilities - current |
|
14,299 |
|
|
79,251 |
|
|
64,952 |
|
|
454.2% |
|
Contract liabilities - long-term |
|
12,303 |
|
|
13,192 |
|
|
889 |
|
|
7.2% |
|
Accounts receivable, which are included in accounts receivable, other current assets and other long-term assets on the consolidated balance sheets, increased by $99.3 million, mainly due to timing. Contract assets, which are included in other current assets on the consolidated balance sheets, decreased by $3.0 million, mainly due to items that became
13
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
fully earned during the period and shifted to accounts receivable, partially offset by the timing of accrual of certain performance incentives. Contract liabilities – current, which are included in accrued liabilities on the consolidated balance sheets, increased by $65.0 million, mainly due to the timing of receipts related to April 2018 revenues and the timing of material rights generated for some of the Company’s government contracts. Contract liabilities – long-term, which are included in deferred credits and other long-term liabilities on the consolidated balance sheets, increased by $0.9 million, mainly due to receipts for which recognition will be long-term.
During the three months ended March 31, 2018, the Company recognized revenue of $11.3 million that was included in current contract liabilities at January 1, 2018. The estimated timing of recognition of amounts included in contract liabilities at March 31, 2018 are as follows: 2018—$78.5 million; 2019—$2.8 million; 2020—$2.6 million; 2021 and beyond—$8.5 million. During the three months ended March 31, 2018, the revenue the Company recognized related to performance obligations that were satisfied, or partially satisfied, in previous periods was not material.
The Company’s accounts receivable consists of amounts due from customers throughout the United States. Collateral is generally not required. A majority of the Company’s contracts have payment terms in the month of service, or within a few months thereafter. The timing of payments from customers from time to time generate contract assets or contract liabilities, however these amounts are immaterial.
Significant Customers
Customers exceeding ten percent of the consolidated Company’s net revenues
The Company has a contract with the State of Florida to provide integrated healthcare services to Medicaid enrollees in the state of Florida (the “Florida Contract”). The Florida Contract began on February 4, 2014 and extends through December 31, 2018, unless sooner terminated by the parties. The State of Florida has the right to terminate the Florida Contract with cause, as defined, upon 24 hour notice and upon 30 days notice for any reason or no reason at all. The Florida Contract generated net revenues of $145.7 million and $152.4 million for the three months ended March 31, 2017 and 2018, respectively.
On July 14, 2017, the State of Florida issued an Invitation to Negotiate for a new contract for its Medicaid managed care program to replace the current contract with the Company and to be effective January 1, 2019. On April 24, 2018 the Company was notified by the Florida Agency for Health Care Administration (“AHCA”) that the Company was not selected to negotiate a new contract to serve as a vendor for its Medicaid managed care program. The Company plans to file a protest with AHCA.
Customers exceeding ten percent of segment net revenues
In addition to the Florida Contract, previously discussed, the following customers generated in excess of ten percent of net revenues for the respective segment for the three months ended March 31, 2017 and 2018 (in thousands):
Segment |
|
Term Date |
|
2017 |
|
2018 |
|
||
|
|
|
|
|
|
|
|
|
|
Healthcare |
|
|
|
|
|
|
|
|
|
Customer A |
|
(1) |
|
$ |
37,374 |
|
$ |
180,457 |
|
Customer B |
|
December 31, 2018 to December 31, 2020 (2) |
|
|
— |
|
|
163,733 |
|
Customer C |
|
December 31, 2022 |
|
|
— |
|
|
117,254 |
|
|
|
|
|
|
|
|
|
|
|
Pharmacy Management |
|
|
|
|
|
|
|
|
|
Customer D |
|
March 31, 2019 |
|
|
92,712 |
|
|
91,442 |
|
(1) |
The Company, along with other participating managed care plans in this state, continues to provide services while a new contract is being finalized. |
14
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
(2) |
The customer has more than one contract. The individual contracts are scheduled to terminate at various points during the time period indicated above. |
Concentration of Business
The Company also has a significant concentration of business with various counties in the State of Pennsylvania (the “Pennsylvania Counties”) which are part of the Pennsylvania Medicaid program, with members under its contract with CMS and with various agencies and departments of the United States federal government. Net revenues from the Pennsylvania Counties in the aggregate totaled $109.9 million and $136.9 million for the three months ended March 31, 2017 and 2018, respectively. Net revenues from members in relation to its contract with CMS in aggregate totaled $111.6 million and $98.4 million for the three months ended March 31, 2017 and 2018, respectively. As of December 31, 2017 and March 31, 2018, the Company had $131.5 million and $118.3 million, respectively, in net receivables associated with Medicare Part D from CMS and other parties related to this business. Net revenues from contracts with various agencies and departments of the United States federal government in aggregate totaled $88.0 million and $84.6 million for the three months ended March 31, 2017 and 2018, respectively.
The Company’s contracts with customers typically have stated terms of one to three years, and in certain cases contain renewal provisions (at the customer’s option) for successive terms of between one and two years (unless terminated earlier). Substantially all of these contracts may be immediately terminated with cause and many of the Company’s contracts are terminable without cause by the customer or the Company either upon the giving of requisite notice and the passage of a specified period of time (typically between 30 and 180 days) or upon the occurrence of other specified events. In addition, the Company’s contracts with federal, state and local governmental agencies generally are conditioned on legislative appropriations. These contracts generally can be terminated or modified by the customer if such appropriations are not made.
Fair Value Measurements
The Company has certain assets and liabilities that are required to be measured at fair value on a recurring basis. These assets and liabilities are to be measured using inputs from the three levels of the fair value hierarchy, which are as follows:
Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
Level 2—Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
Level 3—Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including the Company’s data.
15
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company’s assets and liabilities that are required to be measured at fair value as of December 31, 2017 and March 31, 2018 (in thousands):
|
|
December 31, 2017 |
|
||||||||||
|
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
|
||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents (1) |
|
$ |
— |
|
$ |
284,064 |
|
$ |
— |
|
$ |
284,064 |
|
Investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Government and agency securities |
|
|
28,231 |
|
|
— |
|
|
— |
|
|
28,231 |
|
Obligations of government-sponsored enterprises (2) |
|
|
— |
|
|
22,088 |
|
|
— |
|
|
22,088 |
|
Corporate debt securities |
|
|
— |
|
|
269,788 |
|
|
— |
|
|
269,788 |
|
Taxable municipal bonds |
|
|
— |
|
|
5,000 |
|
|
— |
|
|
5,000 |
|
Certificates of deposit |
|
|
— |
|
|
2,758 |
|
|
— |
|
|
2,758 |
|
Total assets held at fair value |
|
$ |
28,231 |
|
$ |
583,698 |
|
$ |
— |
|
$ |
611,929 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration |
|
$ |
— |
|
$ |
— |
|
$ |
8,817 |
|
$ |
8,817 |
|
Total liabilities held at fair value |
|
$ |
— |
|
$ |
— |
|
$ |
8,817 |
|
$ |
8,817 |
|
|
|
March 31, 2018 |
|
||||||||||
|
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
|
||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents (3) |
|
$ |
— |
|
$ |
229,405 |
|
$ |
— |
|
$ |
229,405 |
|
Investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Government and agency securities |
|
|
33,170 |
|
|
— |
|
|
— |
|
|
33,170 |
|
Obligations of government-sponsored enterprises (2) |
|
|
— |
|
|
22,109 |
|
|
— |
|
|
22,109 |
|
Corporate debt securities |
|
|
— |
|
|
292,480 |
|
|
— |
|
|
292,480 |
|
Certificates of deposit |
|
|
— |
|
|
2,762 |
|
|
— |
|
|
2,762 |
|
Total assets held at fair value |
|
$ |
33,170 |
|
$ |
546,756 |
|
$ |
— |
|
$ |
579,926 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration |
|
$ |
— |
|
$ |
— |
|
$ |
9,050 |
|
$ |
9,050 |
|
Total liabilities held at fair value |
|
$ |
— |
|
$ |
— |
|
$ |
9,050 |
|
$ |
9,050 |
|
(1) |
Excludes $114.7 million of cash held in bank accounts by the Company. |
(2) |
Includes investments in notes issued by the Federal Home Loan Bank, Federal Farm Credit Banks and Federal National Mortgage Association. |
(3) |
Excludes $164.9 million of cash held in bank accounts by the Company. |
For the three months ended March 31, 2018, the Company has not transferred any assets between fair value measurement levels.
The carrying values of financial instruments, including accounts receivable, accounts payable and revolving loan borrowings, approximate their fair values due to their short-term maturities. The fair value of the Notes (as defined below) of $399.0 million as of March 31, 2018 was determined based on quoted market prices and would be classified within Level 1 of the fair value hierarchy. The estimated fair value of the Company’s term loan of $341.2 million as of March 31, 2018 was based on current interest rates for similar types of borrowings and is in Level 2 of the fair value hierarchy. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.
All of the Company’s investments are classified as “available-for-sale” and are carried at fair value.
16
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
As of the balance sheet date, the fair value of contingent consideration is determined based on probabilities of payment, projected payment dates, discount rates, projected operating income, member engagement and new contract execution. The Company used a probability weighted discounted cash flow method to arrive at the fair value of the contingent consideration. As the fair value measurement for the contingent consideration is based on inputs not observed in the market, these measurements are classified as Level 3 measurements as defined by fair value measurement guidance. The unobservable inputs used in the fair value measurement include the discount rate, probabilities of payment and projected payment dates.
As of December 31, 2017 and March 31, 2018, the Company estimated undiscounted future contingent payments of $9.9 million and $9.9 million, respectively. As of March 31, 2018, the aggregate amounts and projected dates of future potential contingent consideration payments were $7.2 million in 2018 and $2.7 million in 2020.
As of December 31, 2017, the fair value of the short-term and long-term contingent consideration was $6.9 million and $1.9 million, respectively, and is included in short-term contingent consideration and long-term contingent consideration, respectively, in the consolidated balance sheets. As of March 31, 2018, the fair value of the short-term and long-term contingent consideration was $6.9 million and $2.2 million, respectively, and is included in short-term contingent consideration and long-term contingent consideration, respectively, in the consolidated balance sheets.
The change in the fair value of the contingent consideration was $(0.1) million and $0.2 million for the three months ended March 31, 2017 and 2018, respectively, which were recorded as direct service costs and other operating expenses in the consolidated statements of income. The increases during 2018 were mainly a result of changes in present value.
The following table summarizes the Company’s liability for contingent consideration for the three months ended March 31, 2018 (in thousands):
|
|
March 31, |
|
|
|
|
2018 |
|
|
Balance as of beginning of period |
|
$ |
8,817 |
|
Changes in fair value |
|
|
233 |
|
Payments |
|
|
— |
|
Balance as of end of period |
|
$ |
9,050 |
|
Cash and Cash Equivalents
Cash equivalents are short-term, highly liquid interest-bearing investments with maturity dates of three months or less when purchased, consisting primarily of money market instruments. At March 31, 2018, the Company’s excess capital and undistributed earnings for the Company’s regulated subsidiaries of $91.5 million are included in cash and cash equivalents.
Investments
If a debt security is in an unrealized loss position and the Company has the intent to sell the debt security, or it is more likely than not that the Company will have to sell the debt security before recovery of its amortized cost basis, the decline in value is deemed to be other‑than‑temporary and is recorded to other‑than‑temporary impairment losses recognized in income in the consolidated statements of income. For impaired debt securities that the Company does not intend to sell or it is more likely than not that the Company will not have to sell such securities, but the Company expects that it will not fully recover the amortized cost basis, the credit component of the other‑than‑temporary impairment is recognized in other‑than‑temporary impairment losses recognized in income in the consolidated statements of income and the non‑credit component of the other‑than‑temporary impairment is recognized in other comprehensive income.
As of December 31, 2017 and March 31, 2018, there were no material unrealized losses that the Company determined to be other‑than‑temporary. No realized gains or losses were recorded for the three months ended
17
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
March 31, 2018
(Unaudited)
March 31, 2017 or 2018. The following is a summary of short‑term and long‑term investments at December 31, 2017 and March 31, 2018 (in thousands):
|
|
December 31, 2017 |
|
||||||||||
|
|
|
|
|
Gross |
|
Gross |
|
|
|
|||
|
|
Amortized |
|
Unrealized |
|
Unrealized |
|
Estimated |
|
||||
|
|
Cost |
|
Gains |
|
Losses |
|
Fair Value |
|
||||
U.S. Government and agency securities |
|
$ |
28,313 |
|
$ |
— |
|
$ |
(82) |
|
$ |
28,231 |
|
Obligations of government-sponsored enterprises (1) |
|
|
22,139 |
|